A Groundbreaking Initiative from the University of Queensland

The University of Queensland (UQ) has announced the launch of the EARLY study, a pivotal research effort aimed at advancing the development of a population-based screening test for ovarian cancer. This study marks a significant step forward in addressing one of Australia's most lethal women's cancers, recruiting approximately 1,500 postmenopausal women aged 50 to 74 from across Queensland. Led by experts at UQ's Centre for Extracellular Vesicle Nanomedicine and Centre for Clinical Research, the initiative underscores the vital role of Australian universities in driving medical breakthroughs.

Ovarian cancer affects nearly 2,000 women annually in Australia, with a five-year survival rate of around 49 percent. The disease's 'silent killer' reputation stems from its late diagnosis in two-thirds of cases, when treatment becomes far more challenging. UQ researchers are targeting this gap by focusing on extracellular vesicles (EVs)—tiny cell-derived particles in the blood that carry proteins and genetic material signaling early cancer presence.

The Critical Need for Effective Ovarian Cancer Screening in Australia

In Australia, ovarian cancer claims over 1,000 lives each year, with projections estimating 1,929 new cases in 2025 alone, according to Cancer Australia. Queensland, home to a significant portion of these cases, sees disproportionate impacts in rural and regional areas where access to specialist care is limited. Unlike breast or cervical cancer, no routine screening exists for ovarian cancer, leading to advanced-stage diagnoses in 70 percent of patients.

Current methods like CA-125 blood tests combined with transvaginal ultrasound (TVUS) have failed large-scale trials such as the UKCTOCS and PLCO studies due to high false-positive rates—up to 9.6 percent cumulatively—and no proven mortality reduction. False positives trigger unnecessary surgeries, anxiety, and complications, highlighting the demand for a precise, non-invasive alternative like UQ's EV-based approach.

Understanding Ovarian Cancer: Risk Factors, Symptoms, and Statistics

Ovarian cancer originates in the ovaries or fallopian tubes, encompassing epithelial, germ cell, and stromal types, with epithelial being most common. Risk factors include age (median diagnosis 65), family history, BRCA1/2 mutations, endometriosis, and never having children, while protective factors encompass oral contraceptives, tubal ligation, breastfeeding, and multiple pregnancies.

Symptoms are often vague—bloating, pelvic pain, appetite changes, urinary urgency—mimicking benign conditions, delaying diagnosis. In Queensland, the Queensland Centre for Gynaecological Cancer Research notes survival jumps to nearly 90 percent for early-stage detection versus under 50 percent overall.

• Australia: 1 in 83 women lifetime risk; 1,929 cases/1,061 deaths projected 2025.
• 5-year survival: 49% (2017-2021), up from 36% (1980s).
• Advanced stage (III/IV): 70% of diagnoses.

These figures emphasize why UQ's research is crucial for higher education's contribution to public health.

Revolutionizing Detection: How the Extracellular Vesicle-Based Test Works

The innovative test isolates EVs from a simple blood draw using INOVIQ's EXO-NET technology, then analyzes protein biomarkers via mass spectrometry and machine learning algorithms. EVs, released by cancer cells, provide a stable 'snapshot' of disease, outperforming traditional markers like CA-125.

Step-by-step process:

1. Blood collection at local pathology (e.g., Sullivan Nicolaides).
2. EV isolation on automated platforms.
3. Biomarker quantification (e.g., MRM-MS).
4. AI classification for high sensitivity/specificity.

Licensed to ASX-listed INOVIQ Ltd by UQ's UniQuest, the test promises scalability for routine screening.

Impressive Validation Results Paving the Way Forward

Prior evaluations on over 530 plasma samples yielded 94% overall accuracy, 92% sensitivity at 96% specificity for all stages, and 91% for Stage I. Recent data shows 100% early-stage detection with just 0.4% false positives—vastly superior to CA-125's 61% sensitivity.

INOVIQ's EXO-OC validation (n=532) confirmed AUC=0.98, PPV=95%, NPV=80%. These metrics position it as a game-changer, minimizing harms from false alarms plaguing past trials.

Inside the EARLY Study: Design, Recruitment, and Logistics

The EARLY study (Evaluating Specificity and feasibility of EARLY Biomarkers for Ovarian Cancer Detection) tests real-world blood handling—collection, storage (various temps), transport, processing—to standardize protocols for population screening.

Eligibility:

• Postmenopausal women 50-74.
• Intact ovaries, no prior ovarian cancer.
• Queensland residents (urban/rural encouraged).

Participation: Quick online survey, consent, one blood draw at SNP centers or UQCCR. Free, safe, ~15 mins. Recruitment now open via gyncan.org.

Leading Researchers Driving UQ's Ovarian Cancer Innovations

Professor Carlos Salomon Gallo heads the UQ Centre for Extracellular Vesicle Nanomedicine, pioneering EV research for obstetrics and gynecology. Quote: “Rapid identification of asymptomatic ovarian cancer will dramatically improve survival.”

Professor Andreas Obermair, gynaecological oncologist at UQ Centre for Clinical Research, leads the Queensland Centre for Gynaecological Cancer Research. Quote: “Early detection means cure rates are very high.” Their work exemplifies university-led translational research.

For aspiring researchers, opportunities abound in research jobs at UQ and similar institutions via higher ed jobs.

Strategic Partnerships and Philanthropic Funding

A 5-year NHMRC grant partners with Ovarian Cancer Research Foundation (>$1.7M to Salomon Gallo) and Lions Medical Research Foundation. Collaborators: Mater Research, Queensland Centre for Gynaecological Cancer. Commercial partner INOVIQ accelerates commercialization.

This ecosystem highlights philanthropy and industry-university ties boosting Australian higher ed research.

Transformative Potential for Women's Health and Regional Equity

Success could enable annual screening like mammograms, catching 90%+ early cases, slashing mortality. Rural QLD women stand to gain most, reducing disparities. Globally, it addresses screening voids, with trials like UKCTOCS underscoring needs.

Implications: Fewer surgeries, better outcomes, economic savings. UQ's model inspires Australian university jobs in biomedical research.

Overcoming Global Challenges in Ovarian Cancer Screening

Past multimodal screening (CA-125/TVUS) faced 4-10% false positives, surgical harms without mortality gains. UQ's test's low FP (0.4%) via EVs/ML offers hope. Ongoing global efforts (ESGO 2026) echo this push.

Photo by Marcus Wallis on Unsplash

Future Outlook: From Study to Standard Care

Post-EARLY, larger trials validate population efficacy, targeting TGA approval. Partnerships position it for clinics by 2030s. UQ's innovation cements Australia's higher ed leadership.

Explore careers in clinical research via higher ed jobs, university jobs, research jobs, or higher ed career advice. Rate professors at Rate My Professor.